Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.